



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/823,317
				Filing Date	April 13, 2004
				First Named Inventor	Wilfried M. Braje, et al.
				Group Art Unit	1614
				Examiner Name	
Sheet	1	of	2	Attorney Docket No.	ABB10043P0012US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
LB		US- 6,342,604 B1	Jan. 29, 2002	BASF Aktiengesellschaft	
		US- 4,577,020	Mar. 18, 1986	The Upjohn Company	
		US- 5,958,923	Sep. 28, 1999	BASF Aktiengesellschaft	
		US- 6,090,807	Jul. 18, 2000	BASF Aktiengesellschaft	
		US- 6,472,392	Oct. 29, 2002	Abbott Laboratories	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
LB		WO 03/002543 A1	Jan. 9, 2003	Abbott Laboratories		
Examiner Signature				Date Considered	5/7/07	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standards ST.16, if possible. ⁶ Applicant is to place a checkmark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/823,317
				Filing Date	April 13, 2004
				First Named Inventor	Wilfried M. Braje, et al.
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	2	Attorney Docket No.	ABB10043P0012US

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ³
LB		J.C. SCHWARTZ, et al., The Dopamine D ₃ Receptor as a Target for Antipsychotics; Novel Antipsychotic Drugs, Raven Press, Ltd., 1992, pp. 135-144; France	
LB		M. DOOLEY, et al., Pramipexole - A Review of Its use in the Management of Early and Advanced Parkinson's Disease; Drugs & Aging, 1998, Vol. 12, pp. 495-514, New Zealand	
LB		J.N. JOYCE, Dopamine D ₃ receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs; Pharmacology & Therapeutics, 2001, 2001, Vol. 90, pp. 231-59, USA	
LB		P. SOLOKOFF, et al, Localization and Function of the D ₃ Dopamine Receptor; Arzneim-Forsch./Drug Res. Vol. 42(1), 1992, pp 224-230, France.	
		P. SOLOKOFF, et al., Molecular cloning and characterization of a novel dopamine receptor (D ₃) as a target for neuroleptics; Nature, 1990, Vol. 347, pp. 146-151, France.	
Examiner Signature		LBernhardt	Date Considered
			5/7/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.